Tag: edoxaban

European Trial Data

European trial data ‘reinforce’ safety profile and efficacy of Lixiana

Daiichi Sankyo Europe has announced outcomes from an observational study in mainly caucasian atrial fibrillation (AF) patients being treated with the anti-coagulation drug edoxaban...
Cardiac Rhythm news for specialists

Low bleeding and cardiovascular events in elderly NVAF patients using edoxaban,...

Daiichi Sankyo has announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients, mostly elderly, treated with edoxaban (Lixiana)....
Cardiac Rhythm news for specialists

Eliminate AF shows low thromboembolic and bleeding events with edoxaban

Uninterrupted anticoagulation with edoxaban (Lixiana, Daiichi Sankyo) resulted in low rates of thromboembolic and bleeding events in patients with atrial fibrillation undergoing catheter ablation,...

Point-of-care testing of coagulation in patients treated with edoxaban

The first systematic evaluation of coagulation point-of-care testing in edoxaban treated patients has been carried out. The results were presented by Florian Härtig, University...
Cardiac Rhythm news for specialists

First patient enrolled in Daiichi Sankyo’s ELIMINATE-AF edoxaban study

The first patient has been enrolled into Daiichi Sankyo’s ELIMINATE-AF study. The multinational, randomised phase 3b study will explore the safety and efficacy of...
Cardiac Rhythm news for specialists

Daiichi Sankyo begins ENTRUST-AF PCI study of once-daily edoxaban

The first patient has been enrolled into Daiichi Sankyo’s ENTRUST-AF PCI study. The multinational, randomised phase 3b study will evaluate a treatment regimen based...
Cardiac Rhythm news for specialists

Health Canada approves edoxaban for two indications

Health Canada has approved edoxaban (Lixiana, Servier Canada) for the prevention of stroke and for systemic embolic events in patients with non-valvular atrial fibrillation,...

ESC 2016: Edoxaban is safe and effective in AF patients undergoing...

ENSURE-AF, the largest prospective, randomised clinical trial to date of anticoagulation for electrical cardioversion in non-valvular atrial fibrillation, has shown that edoxaban is an...

Results of phase 3b ENSURE-AF study investigating edoxaban in AF patients...

Daiichi Sankyo has announced it will present the first results from ENSURE-AF, the largest prospective randomised clinical trial to date evaluating a non-vitamin K...

Sudden cardiac death is the most common cause of death in...

An analysis from the ENGAGE AF-TIMI 48 trial has found that sudden cardiac death was the single most common cause of death and accounted...